Compare UHS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHS | DVA |
|---|---|---|
| Founded | 1978 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.9B |
| IPO Year | 1994 | 2002 |
| Metric | UHS | DVA |
|---|---|---|
| Price | $154.85 | $195.34 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 4 |
| Target Price | ★ $216.36 | $156.75 |
| AVG Volume (30 Days) | ★ 927.7K | 886.8K |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ 37.34 | N/A |
| EPS | ★ 5.65 | 2.87 |
| Revenue | ★ $17,364,829,000.00 | $13,643,069,000.00 |
| Revenue This Year | $7.67 | $3.85 |
| Revenue Next Year | $4.99 | $3.07 |
| P/E Ratio | ★ $27.78 | $68.29 |
| Revenue Growth | ★ 9.71 | 6.46 |
| 52 Week Low | $152.33 | $101.00 |
| 52 Week High | $246.33 | $202.69 |
| Indicator | UHS | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 27.93 | 66.09 |
| Support Level | N/A | $191.57 |
| Resistance Level | $186.67 | $202.69 |
| Average True Range (ATR) | 5.32 | 5.64 |
| MACD | -0.82 | -0.70 |
| Stochastic Oscillator | 1.80 | 52.20 |
Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.